MedTrace Logo

Prognostic Value of Serum Erythropoietin Level,Ferritin Level and Fibrinogen in Adult Low Risk MDS

NCT04573686 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-10-05

No results posted yet for this study

Summary

1. assessment of the penefit of erythropoietin administration in decreasing the frequency of blood transfusion in adult low risk MDS
2. assessement of the clinical significance of the relationship between hyperfibrinogenemia and the prognosis of patients with low risk MDS
3. assessement of the association between serum ferritin levels and patient \_reported aspects and symptomes

Conditions

Interventions

DRUG

Erythropoietin

Erythropoietin will be given subcutenous to all patients

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2022-01-01
Completion
2022-05-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04573686 on ClinicalTrials.gov